NEW YORK (GenomeWeb) – Sequenom has filed a shelf registration to offer from time to time up to $300 million in securities.
In a document filed with the US Securities and Exchange Commission last Friday, the firm said that it may offer securities in the form of common stock, preferred stock, debt securities, warrants, and any combination of the securities.
Net proceeds from any offering will be used for general corporate purposes, including R&D, capital expenditures, working capital, and general and administrative expenses, Sequenom said. Proceeds may also go toward acquisitions and investments in businesses, products, and technologies, though the company said there are no current plans, commitments, or agreements for any such deal.
Last month the company reported $86.8 million in cash, cash equivalents, and marketable securities as of the end of the second quarter.